A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.

A new study aims to help healthcare providers more effectively implement Apretude, a medication used for HIV prevention.

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

Artificial intelligence chatbots could help with the introduction of a twice-yearly shot that can help prevent HIV, experts ...

Cabenuva is administered every two months and was offered to patients who achieved viral suppression from daily treatments.

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

A newly approved HIV prevention drug, lenacapavir, is set to be introduced in at least nine countries in early 2026, and ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

The World Health Organization (WHO) has recommended the global use of injectable lenacapavir (LEN) twice a year to provide near-total ...

In a major advancement in the global fight against HIV, the World Health Organization (WHO) has recommended the use of ...

MSD is advancing its once-monthly oral pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) to Phase III ...